Our Team of Lawyers

About Our Firm

We are honored that thousands of clients have sought our representation in their legal affairs. Our firm consists of lawyers licensed to practice in Texas, Louisiana & Mississippi. In addition to these states, we provide representation to clients in various other parts of the country with proper local co-counsel associations.
Learn more about us

No Obligation, No Cost, Contact Us Today

Free Case Evaluation

Map 1

Baton Rouge7908 Wrenwood Blvd
Baton Rouge, LA 70809

Phone: 866-208-9311
Fax: 866-208-9311

Map 2

Lake CharlesCapital One Tower
Suite 1270
Lake Charles, LA 70629

Phone: 866-208-9311

Map 4

Houston3730 Kirby Drive
Suite 1200
Houston, TX 77098

Phone: 866-208-9311

Map 5

New Orleans1615 Poydras Street
Suite 900
New Orleans, LA 70112

Toll Free: 866-208-9311

Update: Simien & Simien, LLC is open and we are here to help you as we know your needs do not stop. The firm is currently open and operating. In light of current public health concerns, please know that we are following all health guidelines to protect both our team and our clients. We are offering virtual meetings by request.

Attorneys Serving Louisiana, Texas and Mississippi

GAO Report Finds Gaps in the FDA’s oversight of Drug Safety

On Behalf of | Jan 22, 2016 | Defective Products

The Government Accountability Office released a report last week that summarized a list of shortcomings in how the Food and Drug Administration tracks drug safety issues.

In recent years, the FDA has sped up the process of approving many new drugs through expedited programs. Over 1,000 expedited requests were received from October 2006 to December 2014. Just last year, the FDA approved 45 new drugs.

This was the highest number of drugs approved in 19 years, with half of those drugs receiving specialized reviews so that they could reach the market faster.

As new drugs continue to be expedited, the GAO found that the FDA often fails to properly track important safety issues of those drugs.

Between 2008 and 2013, the FDA was late in reviewing more than half of the 1,400 follow up studies it had required of drug manufacturers. These post-market studies are crucial in finding out important safety issues that arise after patients start taking the drugs. These shortcomings could ultimately put more consumers at risk.

Furthermore, the GAO reported that many of the potential safety issues had not yet been uploaded to the FDA’s drug archival tracking system. In interviews, the FDA told the Government Accountability Office that, “it had prioritized identifying, assessing and addressing potential safety issues over administrative tracking,” due to the extensive workload of its review staff.

The Department of Health and Human Services says that the FDA is currently conducting evaluations in order to improve its computerized tracking system for reviewing drugs. The GAO recommends a complete overhaul of the FDA’s database, so that information can be tracked more efficiently and accurately.

If you or someone you know has suffered due to a dangerous prescription drug, the defective product attorneys at Simien and Simien, LLC will fight to get you the justice you deserve. Our personal injury lawyers will work to get you the maximum compensation and closure that you are entitled to have.


FindLaw Network

Free Case Evaluation

Latest From Our Blog

If you are looking for a law firm that has knowledge and experience, you will find it with Simien & Simien, LLC.

Free Case Evaluation

Our team of dedicated Louisiana, Texas and Mississippi attorneys represent injured persons throughout Louisiana, including Alexandria, Opelousas, Baton Rouge, Lafayette, Lake Charles, Houma-Thibodeaux, New Orleans, Shreveport, Monroe, and throughout Mississippi and areas of Texas including Orange, Beaumont, Port Arthur, Austin, San Antonio, Dallas, and Houston and the other metro areas.